Womens Health Innovation Summit

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

Femtech

Technology-enabled products and services addressing women's health, including cycle tracking, fertility, pelvic health, menopause support and connected diagnostics. The category spans consumer apps and regulated medical devices, which is why evidence and reimbursement questions follow it everywhere.

2

Women's health innovation

The commercial and clinical field focused on conditions and life stages that disproportionately or uniquely affect women, such as maternal health, endometriosis, PCOS, menopause, osteoporosis and gynaecological cancers. In practice it covers devices, diagnostics, drugs, digital therapeutics and care-delivery models.

3

Maternal health and maternal morbidity

Care across pregnancy, birth and the postpartum year. Severe maternal morbidity refers to unexpected outcomes of labour and delivery with significant short- or long-term health consequences; reducing it is a common target for monitoring, screening and care-coordination products.

4

Menopause and midlife health

Clinical and product attention to perimenopause and menopause, including hormone therapy, non-hormonal treatment, symptom tracking and workplace support. It has become a distinct commercial segment as employers and payers look at retention and cost of care for women in midlife.

5

Digital therapeutics (DTx)

Software-driven interventions intended to prevent, manage or treat a condition, usually delivered through an app and often supported by clinical evidence. Reimbursement and regulatory status, rather than the software itself, decide whether a DTx reaches patients at scale.

6

SaMD (Software as a Medical Device)

Software intended for a medical purpose that runs on general-purpose hardware rather than being part of a hardware device. In the United States it is regulated by the FDA through pathways such as 510(k), De Novo or, for higher-risk functions, premarket approval.

7

Clinical validation and evidence generation

The studies and real-world data that show a product measures or improves what it claims. For women's health products this often means prospective trials, published endpoints, and data that payers and clinicians will accept when deciding coverage.

8

Reimbursement and coverage

How a product gets paid for: coding (such as CPT or HCPCS), payer medical policy, prior authorisation and employer benefit design. A product can be clinically sound and still stall commercially if no code or coverage pathway exists.

9

Health equity in women's health

The study and correction of avoidable differences in outcomes across race, ethnicity, income, geography and insurance status - for example disparities in maternal mortality, screening access and menopause treatment. It shapes both product design and payer scrutiny.

10

Virtual care and telehealth

Remote delivery of consultation and follow-up, including asynchronous messaging and remote monitoring. In women's health it is often used for contraception, menopause and postpartum support where access or travel is a barrier.

11

Remote patient monitoring (RPM)

Connected devices and wearables that transmit physiological data between visits, such as blood pressure cuffs in pregnancy or symptom trackers in menopause care. Its value depends on workflow integration and whether the data changes clinical decisions.

12

Benefit and employer channel

The route by which employers and health plans purchase women's health services as a covered benefit, often through point-solution vendors. For many startups this channel, not the individual consumer, determines the revenue model.